Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension
(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/9/3051 |
| _version_ | 1797552962096070656 |
|---|---|
| author | Mark Lipphardt Hassan Dihazi Jens-Holger Maas Ann-Kathrin Schäfer Saskia I. Amlaz Brian B. Ratliff Michael J. Koziolek Manuel Wallbach |
| author_facet | Mark Lipphardt Hassan Dihazi Jens-Holger Maas Ann-Kathrin Schäfer Saskia I. Amlaz Brian B. Ratliff Michael J. Koziolek Manuel Wallbach |
| author_sort | Mark Lipphardt |
| collection | DOAJ |
| description | (1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although pathophysiology behind resistant HTN is still not fully understood. There is evidence that selected biomarkers may be involved in the pathophysiology of HTN. (2) Methods: We investigated serum SDC4-levels in patients suffering from resistant HTN before and 6 months after BAT implantation. We collected 19 blood samples from patients with resistant HTN and blood pressure above target and measured serum SDC4-levels. (3) Results: Our results showed high serum SDC4-levels in patients with resistant HTN as compared to a healthy population. Patients with both, resistant HTN and diabetes mellitus type II, demonstrated higher serum SDC4-levels. β-blockers had lowering effects on serum SDC4-levels, whereas calcium channel blockers were associated with higher levels of serum SDC4. BAT implantation did not lead to a significant difference in serum SDC4-levels after 6 months of therapy. (4) Conclusion: Based on our results we propose SDC4 is elevated in patients suffering from resistant HTN. Thus, SDC4 might be a potential marker for endothelial dysfunction in patients with resistant hypertension. |
| first_indexed | 2024-03-10T16:09:36Z |
| format | Article |
| id | doaj.art-4c5292fd37e3410bb775acb66e46dd5d |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T16:09:36Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-4c5292fd37e3410bb775acb66e46dd5d2023-11-20T14:37:00ZengMDPI AGJournal of Clinical Medicine2077-03832020-09-0199305110.3390/jcm9093051Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant HypertensionMark Lipphardt0Hassan Dihazi1Jens-Holger Maas2Ann-Kathrin Schäfer3Saskia I. Amlaz4Brian B. Ratliff5Michael J. Koziolek6Manuel Wallbach7Department of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, 37073 Göttingen, GermanyDepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, 37073 Göttingen, GermanyDepartment of Transfusion Medicine, Göttingen University Medical Center, Georg August University, 37073 Göttingen, GermanyDepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, 37073 Göttingen, GermanyDepartment of Cardiology and Pneumology, Göttingen University Medical Center, Georg August University, 37073 Göttingen, GermanyRenal Research Institute and Departments of Medicine, Pharmacology, and Physiology, New York Medical College, Valhalla, NY 10595, USADepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, 37073 Göttingen, GermanyDepartment of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, 37073 Göttingen, Germany(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although pathophysiology behind resistant HTN is still not fully understood. There is evidence that selected biomarkers may be involved in the pathophysiology of HTN. (2) Methods: We investigated serum SDC4-levels in patients suffering from resistant HTN before and 6 months after BAT implantation. We collected 19 blood samples from patients with resistant HTN and blood pressure above target and measured serum SDC4-levels. (3) Results: Our results showed high serum SDC4-levels in patients with resistant HTN as compared to a healthy population. Patients with both, resistant HTN and diabetes mellitus type II, demonstrated higher serum SDC4-levels. β-blockers had lowering effects on serum SDC4-levels, whereas calcium channel blockers were associated with higher levels of serum SDC4. BAT implantation did not lead to a significant difference in serum SDC4-levels after 6 months of therapy. (4) Conclusion: Based on our results we propose SDC4 is elevated in patients suffering from resistant HTN. Thus, SDC4 might be a potential marker for endothelial dysfunction in patients with resistant hypertension.https://www.mdpi.com/2077-0383/9/9/3051Syndecan-4resistant hypertensionendotheliumbaroreflex activation therapy |
| spellingShingle | Mark Lipphardt Hassan Dihazi Jens-Holger Maas Ann-Kathrin Schäfer Saskia I. Amlaz Brian B. Ratliff Michael J. Koziolek Manuel Wallbach Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension Journal of Clinical Medicine Syndecan-4 resistant hypertension endothelium baroreflex activation therapy |
| title | Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension |
| title_full | Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension |
| title_fullStr | Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension |
| title_full_unstemmed | Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension |
| title_short | Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension |
| title_sort | syndecan 4 as a marker of endothelial dysfunction in patients with resistant hypertension |
| topic | Syndecan-4 resistant hypertension endothelium baroreflex activation therapy |
| url | https://www.mdpi.com/2077-0383/9/9/3051 |
| work_keys_str_mv | AT marklipphardt syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension AT hassandihazi syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension AT jensholgermaas syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension AT annkathrinschafer syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension AT saskiaiamlaz syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension AT brianbratliff syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension AT michaeljkoziolek syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension AT manuelwallbach syndecan4asamarkerofendothelialdysfunctioninpatientswithresistanthypertension |